Industry Insights #PBM #PharmacyClaims

FDA Finalizes the 12-Digit NDC: What the New National Drug Code Format and Barcode Requirements Mean for Healthcare

Billy Buckles

March 24, 2026

12:55

On March 5, 2026, the U.S. Food and Drug Administration published a final rule that will reshape how every drug product in the United States is identified, labeled, and tracked. The rule, titled “Revising the National Drug Code Format and Drug Label Barcode Requirements,” establishes a uniform 12-digit format for the National Drug Code and modernizes barcode requirements to permit both linear and two-dimensional data carriers.

For organizations operating in pharmaceutical pricing, claims adjudication, pharmacy management, and supply chain technology, this is not a distant regulatory footnote. It is a structural change to a foundational data element that touches virtually every system in the healthcare ecosystem. At RxLogic, we view this ruling as both a necessary modernization and a call to action for the industry to begin planning now.

What Is Changing

The National Drug Code has served as the FDA’s standard for uniquely identifying drugs marketed in the United States for decades. Under the current system, the FDA assigns NDCs as 10-digit numbers in one of three segment configurations: 4-4-2, 5-3-2, or 5-4-1. In practice, however, most industry stakeholders work with an 11-digit version of the NDC, which is created by zero-padding the shorter segments to produce a consistent length required for HIPAA-covered electronic transactions such as claims adjudication and reimbursement. This gap between the FDA’s native 10-digit format and the industry’s operational 11-digit standard has been a persistent source of friction, requiring conversion logic, mapping tables, and error-prone transformations throughout healthcare IT systems.

Under the final rule, all FDA-assigned NDCs will transition to a single, uniform 12-digit format structured as follows:

New Uniform NDC Format (6-4-2)

Segment 1 - Labeler Code: 6 digits (identifies the manufacturer, repackager, or distributor)

Segment 2 - Product Code: 4 digits (identifies the specific drug product)

Segment 3 - Package Code: 2 digits (identifies the package configuration)

Existing 10-digit NDCs will be converted by adding leading zeros to the applicable segments. The FDA does not consider this conversion a “new” NDC assignment.

In addition to the format standardization, the FDA is revising its barcode regulations at 21 CFR 201.25 to permit the use of nonlinear barcodes alongside traditional linear barcodes, provided the format conforms to standards developed by a recognized international standards body such as GS1. This is a meaningful modernization that aligns barcode requirements with the two-dimensional data matrix barcodes already mandated under the Drug Supply Chain Security Act (DSCSA) for product tracing.

Notably, beginning March 7, 2033, a single 2D data matrix barcode may satisfy both the NDC barcode label requirement and DSCSA product identifier requirements , encoding the 12-digit NDC alongside serial number, lot number, and expiration date using GS1’s Application Identifier 715.

Why This Matters

At its core, the NDC is the backbone of drug identification across the U.S. healthcare system. It is embedded in claims adjudication, rebate calculations, dispensing workflows, controlled substances reporting, inventory management, and supply chain verification. The move to a single 12-digit format addresses long-standing interoperability challenges, but it also requires coordinated updates across an extraordinary range of systems and stakeholders.

Eliminating Format Variability

The current system’s three different segment configurations (4-4-2, 5-3-2, 5-4-1) and the resulting mismatch between the FDA’s native 10-digit NDC and the 11-digit format used operationally across the industry have created a legacy of conversion logic, mapping tables, and error-prone transformations throughout healthcare IT systems. Every payor, pharmacy, distributor, and data aggregator has had to account for this variability. A single, uniform 12-digit format will reduce errors, streamline data exchange, and eliminate much of the middleware that exists solely to reconcile NDC formats across trading partners.

Supporting DSCSA Convergence

The updated barcode requirements represent a practical step toward reducing label complexity. Today, many pharmaceutical manufacturers are required to carry both a linear barcode for the NDC label requirement and a 2D data matrix barcode for DSCSA compliance. The final rule’s allowance for nonlinear barcodes means that by 2033, manufacturers may consolidate these into a single 2D barcode, reducing label real estate demands and simplifying scanning workflows in pharmacies and hospital settings.

Addressing NDC Exhaustion

A practical driver behind this rule is that the FDA was approaching exhaustion of its pool of available 5-digit labeler codes. The transition to a 6-digit labeler code within the 12-digit format significantly expands the available code space, ensuring the system’s long-term viability as new manufacturers, biologics producers, and private-label distributors continue to enter the market.

Key Dates and Transition Timeline

The FDA has built a deliberately extended timeline to accommodate the breadth of systems and stakeholders affected by this change:

Date	Milestone
March 5, 2026	Final rule published in the Federal Register.
March 2026 – March 2033	Seven-year preparation period. FDA continues assigning 10-digit NDCs. Stakeholders should use this window to update systems, processes, and infrastructure.
March 7, 2033	Effective date. FDA begins assigning 12-digit NDCs. All existing 10-digit NDCs are automatically converted to the 12-digit format in the NDC Directory.
March 2033 – March 2036	Three-year labeling transition. FDA will not object to continued use of 10-digit NDCs on drug labels during this period. Systems must handle both formats.
After March 7, 2036	Enforcement begins. Drug products entering interstate commerce with a 10-digit NDC on the label may be subject to regulatory action.

Importantly, the FDA has indicated it will publish a mapping database linking each existing 10-digit NDC to its corresponding 12-digit NDC, which will be available at least through the end of the transition period.

Who Is Affected

This rule touches virtually every participant in the pharmaceutical supply chain and the broader healthcare data ecosystem:

Manufacturers, repackagers, and relabelers must update product labeling, packaging artwork, and barcode infrastructure.
Pharmacies and health systems must update dispensing systems, inventory management, controlled substances reporting, and point-of-sale platforms.
Payors, PBMs, and claims processors must update claims adjudication logic, rebate systems, formulary databases, and drug pricing engines.
Wholesale distributors and logistics providers must update inventory tracking, purchase order systems, and DSCSA verification infrastructure.
Healthcare IT vendors and drug data publishers must update database schemas, validation rules, data exchange formats, and downstream integrations.
340B covered entities, state reporting agencies, and federal programs that rely on NDCs for utilization tracking, pricing benchmarks, and regulatory reporting.
System readiness: Assess whether existing databases, ERP platforms, and data exchange interfaces can accommodate a 12-digit NDC. Many legacy systems were architected around fixed 10- or 11-digit fields.
Dual-format operations: During the transition period, systems must be capable of handling 10-digit, 11-digit, and 12-digit NDC formats simultaneously. This multi-format requirement extends to every integration point.
Barcode infrastructure: Evaluate whether current scanning hardware and label printing capabilities support 2D data matrix barcodes. Existing UPC-A barcodes cannot accommodate the 12-digit NDC; GS1 has developed Application Identifier 715 to enable encoding in GS1-128, GS1 DataBar, and 2D DataMatrix formats.
Trading partner coordination: The transition only works if stakeholders across the supply chain move in concert. Begin conversations with vendors, distributors, and downstream partners early.
HIPAA and external code sets: The rule affects only FDA-assigned NDCs and does not modify the HIPAA standard 11-digit format used for reimbursement. However, the FDA anticipates that HIPAA standards and related code sets will likely need to be updated in some manner to align with the new format.

The FDA has confirmed that NDC conversions resulting from this rule do not trigger pricing or rebate renegotiation obligations, and that registrants will not need to submit new drug listing files solely for the format change. However, once labeling is updated to reflect the 12-digit NDC, corresponding drug listing files should be updated accordingly.

Practical Considerations for the Industry

While seven years may seem like ample runway, the scope of this change is substantial. Organizations should consider the following as they begin planning:

The RxLogic Perspective

Billy Buckles, SVP of Product & Implementation at RxLogic, shared the following perspective on the ruling:

“The National Drug Code is a critical identifier and very important to our business and our entire ecosystem of products at RxLogic. Our systems support pharmaceutical pricing, claims processing, and pharmacy benefit operations where the NDC drives adjudication logic, rebate calculations, formulary management, and drug identification. Accuracy and consistency in that identifier are non-negotiable.

For our corner of the industry, the most significant aspect of this rule is the resolution of the NDC exhaustion and reuse problem. As the FDA has been running out of available codes under the current 10-digit system, the risk of NDC reuse has been a real and growing concern for claims processors and PBMs. A reused or recycled NDC can create serious downstream issues, from incorrect pricing to misidentified drug products flowing through adjudication. The expanded 12-digit code space directly addresses that risk, and that is where the greatest long-term value of this rule lies for organizations like ours.

The updated barcode and labeling requirements are a welcome modernization as well, particularly the convergence with DSCSA. But from a claims and pharmacy benefits perspective, this is fundamentally about data integrity.

That said, even a structurally simple change, specifically adding leading zeros, has far-reaching implications when the NDC is embedded across hundreds of interconnected systems. We are already evaluating the impact on our platforms and will be working closely with our clients and partners as we develop our transition strategy.”

- Billy Buckles, SVP of Product & Implementation, RxLogic

Looking Ahead

The FDA has signaled clearly: the March 7, 2033 effective date will not be extended. Organizations that start planning now will be best positioned to execute a smooth transition. Those that wait risk compressed timelines, strained vendor resources, and potential disruptions to critical workflows.

We encourage all stakeholders in the pharmaceutical supply chain to review the final rule, assess the impact on their operations, and begin developing transition roadmaps. RxLogic will continue to monitor developments related to this ruling and will share additional guidance as the industry moves toward implementation.

Source Reference

Federal Register: “Revising the National Drug Code Format and Drug Label Barcode Requirements” (FR Doc. 2026-04368), published March 5, 2026.

FDA: National Drug Code Format - https://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/national-drug-code-format

21 CFR 207.33 (NDC Format) and 21 CFR 201.25 (Barcode Label Requirements)

This article is provided for informational purposes only and does not constitute legal or regulatory advice. Organizations should consult with qualified regulatory counsel regarding specific compliance obligations.